These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 12127556)

  • 1. Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
    Tutor O; Díaz MA; Ramírez M; Algara P; Madero L; Martínez P
    Leuk Res; 2002 Sep; 26(9):817-20. PubMed ID: 12127556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
    Dibenedetto SP; Lo Nigro L; Mayer SP; Rovera G; Schilirò G
    Blood; 1997 Aug; 90(3):1226-32. PubMed ID: 9242556
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
    Lauten M; Möricke A; Beier R; Zimmermann M; Stanulla M; Meissner B; Odenwald E; Attarbaschi A; Niemeyer C; Niggli F; Riehm H; Schrappe M
    Haematologica; 2012 Jul; 97(7):1048-56. PubMed ID: 22271901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low relapse rate in children with acute lymphoblastic leukemia after risk-directed therapy.
    Tzortzatou-Stathopoulou F; Papadopoulou AL; Moschovi M; Botsonis A; Tsangaris GT
    J Pediatr Hematol Oncol; 2001 Dec; 23(9):591-7. PubMed ID: 11902303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The presence of minimal residual disease during induction therapy is a reliable factor for the prognosis of recurrence in children with standard-risk B-cell precursor acute lymphoblastic leukemia].
    Tutor-Ureta O; Díaz MA; Algara P; Madero L; Martínez P
    Med Clin (Barc); 1999 Jul; 113(4):129-31. PubMed ID: 10472597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
    Panzer-Grümayer ER; Schneider M; Panzer S; Fasching K; Gadner H
    Blood; 2000 Feb; 95(3):790-4. PubMed ID: 10648387
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia.
    Brisco J; Hughes E; Neoh SH; Sykes PJ; Bradstock K; Enno A; Szer J; McCaul K; Morley AA
    Blood; 1996 Jun; 87(12):5251-6. PubMed ID: 8652840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
    Ratei R; Schabath R; Karawajew L; Zimmermann M; Möricke A; Schrappe M; Ludwig WD
    Klin Padiatr; 2013 May; 225 Suppl 1():S34-9. PubMed ID: 23700065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term results of AIEOP-8805 protocol for acute B-cell lymphoblastic leukemia of childhood.
    Pillon M; Aricò M; Basso G; Locatelli F; Citterio M; Micalizzi C; Testi AM; Barisone E; Nardi M; Lombardi A; Rondelli R; Rosolen A;
    Pediatr Blood Cancer; 2011 Apr; 56(4):544-50. PubMed ID: 21298738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p16 inactivation associated with aggressive clinical course and fatal outcome in TEL/AML1-positive acute lymphoblastic leukemia.
    Papadhimitriou SI; Polychronopoulou S; Tsakiridou AA; Androutsos G; Paterakis GS; Athanassiadou F
    J Pediatr Hematol Oncol; 2005 Dec; 27(12):675-7. PubMed ID: 16344676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of early anthracycline dose-intensity according to expression of Philadelphia chromosome/BCR-ABL rearrangements in B-precursor adult acute lymphoblastic leukemia.
    Bassan R; Rohatiner AZ; Lerede T; Di Bona E; Rambaldi A; Pogliani E; Rossi G; Fabris P; Morandi S; Casula P; Carter M; Lambertenghi-Deliliers G; Lister TA; Barbui T
    Hematol J; 2000; 1(4):226-34. PubMed ID: 11920195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methotrexate polyglutamation may lack prognostic significance in children with B-cell precursor acute lymphoblastic leukemia treated with intensive oral methotrexate.
    Mantadakis E; Smith AK; Hynan L; Winick NJ; Kamen BA
    J Pediatr Hematol Oncol; 2002 Nov; 24(8):636-42. PubMed ID: 12439035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
    Coustan-Smith E; Sancho J; Hancock ML; Boyett JM; Behm FG; Raimondi SC; Sandlund JT; Rivera GK; Rubnitz JE; Ribeiro RC; Pui CH; Campana D
    Blood; 2000 Oct; 96(8):2691-6. PubMed ID: 11023499
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of IKZF1 deletions in association with vincristine-dexamethasone pulses during maintenance treatment of childhood acute lymphoblastic leukemia on trial ALL-BFM 95.
    Hinze L; Möricke A; Zimmermann M; Junk S; Cario G; Dagdan E; Kratz CP; Conter V; Schrappe M; Stanulla M
    Leukemia; 2017 Aug; 31(8):1840-1842. PubMed ID: 28529312
    [No Abstract]   [Full Text] [Related]  

  • 16. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current results of studies of immunophenotype-, age- and leukocyte-based therapy for children with acute lymphoblastic leukemia. The Pediatric Oncology Group.
    Crist W; Shuster J; Look T; Borowitz M; Behm F; Bowman P; Frankel L; Pullen J; Krance R; Steuber P
    Leukemia; 1992; 6 Suppl 2():162-6. PubMed ID: 1578922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.
    Horibe K; Yumura-Yagi K; Kudoh T; Nishimura S; Oda M; Yoshida M; Komada Y; Hara J; Tawa A; Usami I; Tanizawa A; Kato K; Kobayashi R; Matsuo K; Hori H;
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):81-89. PubMed ID: 28169879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
    Ruano D; Diaz MA; Tutor O; Garcia-Sanchez F; Martinez P; Madero L
    Haematologica; 2000 Aug; 85(8):877-8. PubMed ID: 10942942
    [No Abstract]   [Full Text] [Related]  

  • 20. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
    Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
    Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.